PFSA Profusa, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1859807 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY23.0%
TTM EPS YoY197.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-155.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets73.0%
Debt / equity0.00x
Current ratio0.02x
Interest coverage-174.12x
Cash quality & payout
Operating cash flow / net income0.47x
Accruals ratio-82.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | $100,000 | — | — |
| R&D expense | $2.80M | $1.61M | — | — |
| SG&A expense | $24.90M | $2.99M | — | — |
| Operating income | -$27.71M | -$4.50M | -$1.51M | -$1.27M |
| Interest expense | $2.52M | $4.42M | — | — |
| Pretax income | — | -$8.63M | $1.62M | $7.67M |
| Income tax | — | $80,513 | $456,790 | $499,211 |
| Net income | -$35.82M | -$9.23M | $1.16M | $7.17M |
| EPS (basic) | -107.01 | -357.14 | 0.12 | 0.30 |
| EPS (diluted) | -107.01 | -357.14 | 0.12 | 0.30 |
| Weighted avg. shares (diluted) | 334,762 | 25,844 | 5.19M | 5.19M |
| Balance sheet | ||||
| Cash & equivalents | $1.78M | $191,000 | $142,000 | $193,486 |
| Current assets | $3.76M | $260,000 | $1.58M | $511,704 |
| PP&E, net | $8,000 | — | — | — |
| Total assets | $3.77M | $3.07M | $10.88M | $194.74M |
| Current liabilities | $22.26M | $57.13M | $4.92M | $935,751 |
| Short-term debt | — | — | $200,000 | — |
| Total liabilities | $30.43M | $57.13M | $5.09M | $1.83M |
| Shareholders' equity | -$26.66M | -$119.20M | -$110.00M | -$619,476 |
| Shares outstanding | 12,320 | 25,844 | 5.19M | 5.19M |
| Cash flow statement | ||||
| Operating cash flow | -$16.25M | -$2.07M | -$2.06M | -$581,189 |
| Capital expenditure | $8,000 | — | — | — |
| Free cash flow | -$16.26M | — | — | — |
| Investing cash flow | -$2.01M | $2.97M | $185.60M | $33,447 |
| Financing cash flow | $19.84M | $2.12M | -$183.72M | — |
| Stock-based compensation | $891,000 | $21,000 | — | — |
| Share buybacks | — | $3.25M | $184.85M | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.